Arbutus Biopharma Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arbutus Biopharma Corporation
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.
BTIG analyst expects SeaSpine’s acquisition of 7D Systems will help SeaSpine morph into a procedurally integrated solutions provider.
Shanghai Henlius Biotech is planning to move forward with wet AMD trials for its bevacizumab biosimilar rival to Avastin following a nod from the US FDA.
After an earlier frenzy around local production and supply, policies to encourage generics, and fast-evolving procedural streamlining, Pfizer’s $350m ambition to develop and make cheaper biologics in China has come to an abrupt halt with the sale of its manufacturing site in a deal with services heavyweight WuXi Apptec.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Genevant Sciences
- Inex Pharmaceuticals Corporation
- OnCore Biopharma, Inc, (Enantigen Therapeutics, Inc.)
- Tekmira Pharmaceuticals Corporation (TKMR)
- Protiva Biotherapeutics Inc.